Evaluate the Safety and Efficacy of Botulax® as Compared to Botox® in Subject With Moderate to Severe Crow's Feet Lines
Launched by HUGEL · Jan 22, 2018
Trial Information
Current as of May 09, 2025
Completed
Keywords
ClinConnect Summary
1. Allocation: Randomized
2. Masking: Double Blind
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male or female of at least 19 to 65 years old
- • Bilaterally symmetrical moderator-to-severe CFL at maximum smile on the FWS as rated by the investigator
- Exclusion Criteria:
- • Subject with hypersensitivity to the investigational products or their components
- • Female subject who are pregnant or lactating
- • Subject who are unable to communicate or follow the instructions
- • Subject who are not eligible for this study based on the judgment of an investigator
About Hugel
Hugel is a leading biopharmaceutical company focused on the development and commercialization of innovative aesthetic and therapeutic solutions. With a commitment to advancing healthcare, Hugel specializes in the production of high-quality injectable products, including botulinum toxin and dermal fillers, designed to enhance patient outcomes in aesthetic medicine. The company adheres to rigorous standards of safety and efficacy, conducting comprehensive clinical trials to ensure that its products meet the highest regulatory requirements. Through continuous research and development, Hugel aims to expand its portfolio and improve the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, , Korea, Republic Of
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials